Evidence review / Preclinical record
TB-500 Research: What Is Verified, What Is Preclinical, and What Is Full-Length Thymosin Beta-4
The mechanism, the findings, and the null results — each graded against the published literature and the fragment-versus-parent-protein caveat.
TB-500 Mechanism of Action: Actin Sequestration and Cell Migration
TB-500 research begins at the cytoskeleton. The Ac-LKKTETQ fragment carries the actin-binding motif of thymosin beta-4, the major intracellular G-actin-sequestering peptide [5]. Full-length thymosin beta-4 binds monomeric (globular) actin 1:1 and caps both ends of the monomer, holding a buffered pool of unpolymerized actin and regulating cytoskeletal dynamics, cell migration and motility [1]. X-ray crystallography of a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, resolved to 2 Å, established this 1:1 sequestration and the dual-end capping, and identified the WH2 actin-interacting motif as the structural basis [1].
In injury models, thymosin beta-4 and the LKKTETQ region are associated with accelerated cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, reduced myofibroblast and scar formation, and recruitment of progenitor cells [5]. A consolidating review framed thymosin beta-4 as an actin-sequestering protein that "moonlights" to repair injured tissues, integrating its cytoskeletal and regenerative roles [9].
The honest gap is the seven-mer itself. Whether the isolated Ac-LKKTETQ fragment reproduces the full protein's downstream effects at the doses used in peptide research is not established in controlled human trials [5]. The mechanism is verified for the parent protein; its faithful transfer to the fragment is an open question.
Thymosin Beta-4: The Parent Protein Behind TB-500
Thymosin beta-4 is a ubiquitous 43-amino-acid peptide of approximately 4963 Da, encoded by TMSB4X and present in nearly all human cells [5]. It is the body's principal G-actin-sequestering molecule, and its residues 17-23 — the LKKTETQ segment — are the actin-binding core that TB-500 reproduces [5].
The distinction is the central caveat of this entire record. "TB-500" in commerce and in anti-doping science is the ~889 Da heptapeptide, but the overwhelming majority of efficacy studies were conducted with full-length thymosin beta-4 (~4963 Da) [7]. It is not established that the seven-mer reproduces the parent protein's effects, so much TB-500 marketing leans on full-length thymosin beta-4 data [5][7]. One mechanistic detail underscores the gap: Ac-SDKP, an N-terminal cleavage product of full-length thymosin beta-4 with its own anti-fibrotic and angiogenic activity, is generated from the protein's N-terminus and is NOT produced by the C-terminal-region TB-500 fragment [5]. Wherever this site reports a thymosin beta-4 finding, it is labeled as such — the fragment's name does not inherit the parent protein's evidence.
Effects Observed in Preclinical TB-500 and Thymosin Beta-4 Research
Reported TB-500 benefits trace to a preclinical literature on full-length thymosin beta-4 spanning wound healing, muscle and connective-tissue repair, cardiac protection, angiogenesis, neurological recovery and hair-follicle biology [5]. The strongest single wound finding: in a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold [3].
A review by Goldstein and colleagues consolidated the mechanism: thymosin beta-4 binds actin, promotes cell mobilization and stem-cell activity, decreases myofibroblast number to reduce scarring, is released by platelets and macrophages after injury to limit apoptosis and inflammation, and promotes angiogenesis — the rationale that carried it into clinical trials for dermal wounds, corneal injury and heart and CNS repair [5]. A dedicated review of thymosin beta-4 in dermal healing summarized the same skin-repair activity across the wound literature [10].
The record is graded, not cheered. These are preclinical and full-length-protein findings; no completed controlled human trial of the fragment confirms any of them for the seven-mer [6].
TB-500 and BPC-157: How the Two Recovery Peptides Are Compared
TB-500 and BPC-157 are the two peptides most often co-searched for tissue repair, and the honest comparison is structural, not clinical. No head-to-head human trial of the two exists, and a 2026 narrative review in Sports Med listed both among unapproved peptides that show favorable tissue-repair outcomes in animal models but for which rigorous human safety data are scarce, with potential for serious harm and operation largely outside regulatory oversight [13].
What can be said is that the two work through different described mechanisms. TB-500's rationale is actin sequestration and cell migration via the thymosin beta-4 motif [1][5]; BPC-157's preclinical literature centers on angiogenic and cytoprotective pathways. Both share the same evidentiary ceiling: a large animal record and an absent controlled human-efficacy record. Comparisons that rank them for human outcomes are not supported by the literature. Both also share a regulatory boundary — see TB-500 legal status and 503A compounding.
Cardiac, neurological, and hair findings
The cardiac and neurological literature is where thymosin beta-4 drew the most clinical interest, and where the null results are most instructive. In mice, thymosin beta-4 formed a complex with PINCH and integrin-linked kinase that activated the survival kinase Akt, promoted cardiac and endothelial cell migration, and — after coronary artery ligation — enhanced early myocyte survival and improved cardiac function [2]. Counter-evidence exists: systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, tempering the cardiac narrative.
In the brain, a dose-response study is the most careful single experiment in the record. Male Wistar rats with embolic middle cerebral artery occlusion received intraperitoneal thymosin beta-4 at 2, 12 or 18 mg/kg starting 24 hours post-stroke, then every three days for four more doses; 2 and 12 mg/kg improved neurological function significantly from day 14 through day 56, but 18 mg/kg gave no significant benefit, with a modeled optimal dose near 3.75 mg/kg [4]. The non-monotonic curve is a direct rebuttal of community "more is better" reasoning [4].
In hair biology, thymosin beta-4 at nanomolar concentrations stimulated hair growth in rats and mice by activating hair-follicle bulge stem cells, and an independent mouse study corroborated hair-growth promotion [11]. Human hair-growth efficacy for the fragment is unproven.